Exercise of Options

Abzena plc

Exercise of options

Cambridge, UK, 4 July 2017 - Abzena plc (AIM: ABZA, 'Abzena', the 'Company' or the 'Group') announces that on 4th July 2017, 35,333 new ordinary shares of £0.002 each in the Company ('Ordinary Shares') were issued and allotted following the exercise of share options. The new Ordinary Shares rank pari passu with the Company's existing issued Ordinary Shares and have been admitted to trading on AIM under the Company's block admission.

Total voting rights

Following the issue of 35,333 new Ordinary Shares pursuant to the option exercise set out above, the Company's issued share capital comprises 213,639,236 Ordinary Shares with voting rights. No Ordinary Shares are held in Treasury. The total number of voting rights in the Company is therefore 213,639,236. This figure of 213,639,236 Ordinary Shares may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

-Ends-

Enquiries:

Notes to Editors

About Abzena

Abzena (AIM: ABZA) provides proprietary technologies and complementary services to enable the development and manufacture of biopharmaceutical products.

The term 'Abzena inside' is used by Abzena to describe products that have been created using its proprietary technologies and are being developed by its partners, and include Composite Human Antibodies™ and ThioBridge™ Antibody Drug Conjugates (ADCs). Abzena has the potential to earn future licence fees, milestone payments and/or royalties on 'Abzena inside' products.

Abzena offers the following services and technologies across its principal sites in Cambridge (UK), San Diego, California (USA) and Bristol, Pennsylvania (USA):

· Immunology research studies, including immunogenicity assessment of candidate biopharmaceutical products;

· Protein engineering to create humanized antibodies and deimmunised therapeutic proteins;

· Cell line development for the manufacture of recombinant proteins and antibodies;

· Contract process development and GMP manufacture of biopharmaceuticals, including monoclonal antibodies and recombinant proteins for preclinical and clinical studies;

· Contract synthetic chemistry and bioconjugation research services, focused on antibody-drug conjugates (ADCs);

· Proprietary site-specific conjugation technologies and novel payloads for ADC development; and

· GMP manufacturer of ADC linkers, payloads & combined linker-payloads.

For more information, please see www.abzena.com